We are excited to share that Chun (Michael) Chen, PharmD, from Burning Rock Dx, will be presenting at the Immuno-Oncology Xchange run by hubXchange Join us for his keynote presentation titled: "Exploring the potential: harnessing ctDNA MRD in immune-oncology treatment for solid tumors." 🗓 Date: June 18, 2024 🕒 Time: 8:30 - 9:00 AM 📍 Woburn Hilton Hotel, Boston MA 01801 In addition, our talented team members ，Shawn A. , Alex Brand and Liliang Jin will also be attending the conference. This is a fantastic opportunity to connect and discuss the latest advancements in immuno-oncology. #ImmunoOncology #CancerResearch #BurningRockDx #ctDNA #MRD
Burning Rock Dx’s Post
More Relevant Posts
-
#SITC2023 Come and have a chat with Alexy Promonet (poster 206) about spatial transcriptomics solutions we are offering with FFPE samples.
Cerba Research will be present at SITC 2023, the 38th annual meeting, November 1-5 in San Diego! Don’t hesitate to meet our expert Alexy Promonet for the poster presentation “ Validation of Nanostring® technologies for solid tumor clinical studies: Robustness, precision, and inter-site comparison.” This is an excellent opportunity to discover how we can accelerate your research with extensive data from a limited tissue sample. #SITC #TransformingResearch #AdvancingHealth
-
-
Yesterday at #ASCO24, Shasqi’s Founder & CEO, José M. Mejía Oneto presented data from our Phase 2a study in patients with soft tissue sarcoma. This trial represents the first successful dose escalation of doxorubicin beyond 4x in a clinical trial: using our CAPAC technology to activate chemotherapy at the tumor, we were able to dose 12x the standard dose of doxorubicin per cycle without any DLTs, and with mild and manageable myelosuppression. Thanks to our PIs: Nam Bui, Vineet Kwatra, Christopher W. Ryan, MD, Erlinda Maria Gordon MD and Sant Chawla and to the patients and their families for participating in this study. Read the full poster here👇 https://bit.ly/3VpEuHR
-
-
Early is Good presented multi-omics detection platform at #acsfall2023. Check out the abstract here: https://lnkd.in/g3fV_7DC #multiomics #bladdercancer #bcdx Thakshila Liyanage Asel Liyanage
-
-
Missed the Vizgen & Labroots #Webinar on unlocking the secrets of #Glioblastoma with #SpatialMultiomic analysis? It's not too late! 🌟 You can still access all the insights shared by Prof. Heiland from FAU Erlangen-Nürnberg by watching the webinar on-demand. Dive into their groundbreaking work on therapy resistance and tumor microenvironment changes. 👉 Register to Watch On-Demand: https://hubs.ly/Q02t6r5W0 #Vizgen #MERSCOPE #GlioblastomaResearch #CancerResearch #OnDemandLearning
-
-
Struggling to visualize cell distribution in #immunotherapy research? Cryo-fluorescence Tomography (CFT) might be your solution. Matthew Silva, PhD, the CEO of Emit Imaging, presents our upcoming webinar “Revolutionizing Immunotherapy Research with 3D, Multiplexed Cryo-fluorescence Tomography”, which you can register for here 🔽 https://bit.ly/3sdBTom #CancerImmunotherapy #CancerResearch
-
-
Amazing webinar by Dr. Patrick Schmidt from DKFZ. Humbled by the level of innovation and ambition and science that must go into developing a successful CAR-T therapy for solid tumor and grateful that our Beacon series of platform could play a key part! Dr. Schmidt's team must uncover a tumor target, construct a new CAR delivery mechanism, build a new CAR library from donors in DNA and in cells, build a reporter system (using our Beacon!), then screen functionally 10's of thousands of the CAR-T library (using our Beacon!) to look for the construct that has the right functional attributes, then sequence the identified clones and validate them in a functional assay! The combination of science and technology ultimately will yield a shorter time to deliver CAR-T therapy to patients - since today the 40 day delay is just too long and 40% of the patients die from waiting. Let's do this - so amazing to deliver our technology to help with improving human health. Log into the webinar to join the fight against cancer with Dr. Schmidt! https://lnkd.in/gjG8arfr #Brukercellularanalysis #Beacon
-
Senior Field Application Scientist @ Bruker Cellular Analysis | Expertise in Cytometry, Cell Biology and Biochemistry
Using the digital cell biology platform from Bruker Cellular Analysis, Dr Patrick Schmidt demonstrates the power of function-first characterisation of CAR-T cells, at single cell resolution. Linking function, to phenotype to genotype on a single device - the Beacon Optofluidic System has been driving pharmaceutical endeavours for years before entering academia. Get in touch to learn more. #beaconquest #digitalcellbiology #beacon #celltherapy #cartcelltherapy #OEP #optofluidic #antibodydiscovery #celldevelopment #quest #beyondphenotype
Amazing webinar by Dr. Patrick Schmidt from DKFZ. Humbled by the level of innovation and ambition and science that must go into developing a successful CAR-T therapy for solid tumor and grateful that our Beacon series of platform could play a key part! Dr. Schmidt's team must uncover a tumor target, construct a new CAR delivery mechanism, build a new CAR library from donors in DNA and in cells, build a reporter system (using our Beacon!), then screen functionally 10's of thousands of the CAR-T library (using our Beacon!) to look for the construct that has the right functional attributes, then sequence the identified clones and validate them in a functional assay! The combination of science and technology ultimately will yield a shorter time to deliver CAR-T therapy to patients - since today the 40 day delay is just too long and 40% of the patients die from waiting. Let's do this - so amazing to deliver our technology to help with improving human health. Log into the webinar to join the fight against cancer with Dr. Schmidt! https://lnkd.in/gjG8arfr #Brukercellularanalysis #Beacon
How to Speed Up the Cell Therapy Development Processes: Advancing CAR T Manufacturing Using Single Cell Analysis - Bruker Cellular Analysis
https://brukercellularanalysis.com
-
Day 3 at #PepTalk2024. Today's topic is about how our MHC Monomers & Tetramers can help in facilitate tumor research and development. Our products come in several formats and exhibit high stability. If you are having trouble finding our poster #B20, don't worry - just come by our booth #217 and we'll give you all the information you need. We are excited to connect with all of you and exchange ideas! #KACTUS #CHIPepTalk #Antibodies #AntibodyTherepeutics #ProteinEngineering #AntibodyDiscovery #AntibodyCharacterization
-
-
Come see us at the upcoming American Heart Association Scientific Sessions conference in Philly this Saturday, November 11th at 9:30 AM! Alex Yi, Our VP of Clinical Development will be presenting a moderated oral presentation on our novel immunotherapy research: Blockade of CD47 Using a Novel Anti-CD47 Molecule, BRB-002, Attenuates Atherosclerosis in an ApoE Mouse Model in the Science and Technology Hall, Level 2, MDP8. #AHA2023 , #CD47 , #atherosclerosis
-
-
Radiopharmaceuticals have come a long way in the past decade, however, there are still numerous opportunities in this exciting field to further improve treatment outcomes for cancer patients around the world. Join Clarity’s Executive Chairperson, Dr Alan Taylor, on the Science Hat Podcast to learn how copper isotope manufacturing and logistics will enable global reach of radiopharmaceuticals and maximise the benefit for patients. Click on the following link to watch previous episodes of the Science Hat Podcast and learn more about Clarity’s Targeted Copper Theranostic (TCT) platform that uses Cu-64 for imaging and Cu-67 for therapy: https://lnkd.in/dmDVYYU4 #radiopharmaceuticals #theranostics #TCT
Global pharmaceutical services on companion diagnostics（CDx) developing/clinical biomarker detection/ #MRD /precision medicine/NGS tumor panels/ctDNA cfDNA MCED / BD with Biotech /Pharma/MNC w/ CLIA/CAP clinical lab
1moBe there!